drugset / Trial / NCT01096056
Trial to Evaluate the Safety and the Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2186877A in Healthy Children
RandomizedParallel-groupOpen-labelPrevention
Summary
The purpose of this study is to evaluate the safety and immunogenicity of GlaxoSmithKline Biologicals' influenza vaccine GSK2186877A in healthy children 6 to 35 months of age. This Protocol Posting has been updated following Amendment 1 of the Protocol, Jun 2010. The impacted sections are study design, outcome measures, intervention sections and number of subjects.
Timeline
- Start
- 2010-04-05
- Primary completion
- 2010-12-13
- Completion
- 2010-12-13
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Influenza vaccine GSK2186877A formulation 1 | Vaccine | — | Intramuscular |
| Subject | Influenza vaccine GSK2186877A formulation 2 | Vaccine | — | Intramuscular |
| Background | Influenza Virus Vaccine | Vaccine | — | Intramuscular |